期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 78, 期 3, 页码 227-242出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2010.06.001
关键词
Elderly; Targeted therapy; Small molecule inhibitors; Monoclonal antibodies
Cancer is a disease of the elderly with the majority of new diagnoses and deaths from cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in the elderly is the preservation of functional independence and quality of life. The advent of targeted therapies has raised the hope that older patients with cancer could be treated as effectively as younger patients and without added toxicities. However, caution must be exercised while addressing the use of these therapies in the elderly population and only after taking into consideration the risks, benefits and prognosis of patients on an individual basis. This article reviews the current literature on the efficacy, cost-effectiveness and toxicity of the currently approved targeted agents in the elderly population. Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据